TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

~ Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technology ~ Collaboration focused on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery ~ Catalent to offer TFF Pharmaceuticals’ innovative Thin Film Freezing technology to complement its own capabilities of spray-drying for dry powder inhalation

Daniel Carlson

March 1, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

3 COMMENTS

pfalker March 2, 2022 at 12:48 pm

You need to login to view this content.

Reply
- Daniel Carlson March 2, 2022 at 12:51 pm
  
  You need to login to view this content.
  
  Reply
  - pfalker March 2, 2022 at 1:01 pm
    
    You need to login to view this content.
    
    Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.